Evidence map›Paper›PMID 29028303›Full record

ArticleACS nano2017

Neutrophil-Particle Interactions in Blood Circulation Drive Particle Clearance and Alter Neutrophil Responses in Acute Inflammation.

Catherine A Fromen, William J Kelley, Margaret B Fish, Reheman Adili, Jeffery Noble, Mark J Hoenerhoff, Michael Holinstat, Omolola Eniola-Adefeso

Abstract read
In one paragraph

Article in ACS nano, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed.

  1. Article
  2. Article
  3. Modulating Calcium Homeostasis via a Biomimetic Scaffold to Rescue Diabetic Ischemic Wounds.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Nanoparticle-Based Pulmonary Immune Engineering.Annual review of chemical and biomolecular engineering · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Catherine A FromenDepartment of Chemical Engineering, University of Michigan , Ann Arbor, Michigan 48109, United States.ORCID 0000-0002-7528-0997
William J KelleyDepartment of Chemical Engineering, University of Michigan , Ann Arbor, Michigan 48109, United States.
Margaret B FishDepartment of Chemical Engineering, University of Michigan , Ann Arbor, Michigan 48109, United States.
Reheman AdiliDepartment of Pharmacology, University of Michigan , Ann Arbor, Michigan 48109, United States.
Jeffery NobleDepartment of Chemical Engineering, University of Michigan , Ann Arbor, Michigan 48109, United States.
Mark J HoenerhoffIn Vivo Animal Core, Unit for Laboratory Animal Medicine, University of Michigan , Ann Arbor, Michigan 48109, United States.
Michael HolinstatDepartment of Pharmacology, University of Michigan , Ann Arbor, Michigan 48109, United States.
Omolola Eniola-AdefesoDepartment of Chemical Engineering, University of Michigan , Ann Arbor, Michigan 48109, United States.ORCID 0000-0002-8728-6608

Funding

Role of 12-lipoxygenase in platelet reactivity and type 2 diabetes mellitusR01HL114405 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HOLINSTAT, MICHAEL ALLAN · 2013 to 2017
$1.9M
Training Program in Translational Cardiovascular Research and EntrepreneurshipT32HL125242 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MICHELE, DANIEL E · 2015 to 2024
$1.9M
Role of carrier plasma protein corona in their vascular wall localizationR01HL115138 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ENIOLA-ADEFESO, OMOLOLA · 2012 to 2016
$1.9M
12-HETrE regulation of plateletsR01GM105671 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HOLINSTAT, MICHAEL ALLAN · 2013 to 2017
$1.6M
Deformable hydrogel carriers for enhanced transport in nanoparticle drug deliveryF31HL132567 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FISH, MARGARET BROOKS · 2016 to 2017
$50k
Nanotechnology in Medicine: From Molecules to HumansR13EB023103 · NIBIB · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ENIOLA-ADEFESO, OMOLOLA · 2016 to 2016
$13k
NHLBI NIH HHS F31 HL132567NHLBI NIH HHS R01 HL114405NHLBI NIH HHS R01 HL115138NHLBI NIH HHS T32 HL125242NIBIB NIH HHS R13 EB023103NIGMS NIH HHS R01 GM105671
6 · The paper itself

Abstract

Although nano- and microparticle therapeutics have been studied for a range of drug delivery applications, the presence of these particles in blood flow may have considerable and understudied consequences to circulating leukocytes, especially neutrophils, which are the largest human leukocyte population. The objective of this work was to establish if particulate drug carriers in circulation interfere with normal neutrophil adhesion and migration. Circulating blood neutrophils in vivo were found to be capable of rapidly binding and sequestering injected carboxylate-modified particles of both 2 and 0.5 μm diameter within the bloodstream. These neutrophil-particle associations within the vasculature were found to suppress neutrophil interactions with an inflamed mesentery vascular wall and hindered neutrophil adhesion. Furthermore, in a model of acute lung injury, intravenously administered drug-free particles reduced normal neutrophil accumulation in the airways of C57BL/6 mice between 52% and 60% versus particle-free mice and between 93% and 98% in BALB/c mice. This suppressed neutrophil migration resulted from particle-induced neutrophil diversion to the liver. These data indicate a considerable acute interaction between injected particles and circulating neutrophils that can drive variations in neutrophil function during inflammation and implicate neutrophil involvement in the clearance process of intravenously injected particle therapeutics. Such an understanding will be critical toward both enhancing designs of drug delivery carriers and developing effective therapeutic interventions in diseases where neutrophils have been implicated.

Indexed as

AnimalsCell AdhesionCell MovementHumansInflammationLiverMiceNanoparticlesNeutrophilsdrug carriersinflammationleukocytesnanoparticlesneutrophils

Identifiers

PMID29028303
PMCPMC5709153

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.